Zacks Investment Research Upgrades Vivos Therapeutics (NASDAQ:VVOS) to “Hold”

Vivos Therapeutics (NASDAQ:VVOS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising mild-to-moderate obstructive sleep apnea. Vivos Therapeutics Inc. is based in Highlands Ranch, Colorado. “

Separately, Roth Capital reduced their price objective on shares of Vivos Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 13th.

Shares of NASDAQ:VVOS traded up $0.16 during midday trading on Thursday, hitting $3.66. The stock had a trading volume of 143,134 shares, compared to its average volume of 1,225,698. Vivos Therapeutics has a 12 month low of $2.61 and a 12 month high of $14.41. The business’s 50-day simple moving average is $4.26 and its 200-day simple moving average is $5.29. The company has a market cap of $83.49 million and a P/E ratio of -2.61.

Vivos Therapeutics (NASDAQ:VVOS) last released its earnings results on Thursday, August 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). The company had revenue of $4.50 million for the quarter, compared to analyst estimates of $3.70 million. On average, research analysts predict that Vivos Therapeutics will post -0.7 EPS for the current year.

A number of hedge funds have recently bought and sold shares of VVOS. BlackRock Inc. acquired a new position in Vivos Therapeutics in the first quarter valued at about $77,000. Geode Capital Management LLC acquired a new position in Vivos Therapeutics in the first quarter valued at about $82,000. Avalon Investment & Advisory acquired a new position in Vivos Therapeutics during the first quarter worth about $1,125,000. Alpha Paradigm Partners LLC acquired a new position in Vivos Therapeutics during the first quarter worth about $66,000. Finally, Citadel Advisors LLC acquired a new position in Vivos Therapeutics during the first quarter worth about $105,000. 10.29% of the stock is owned by institutional investors and hedge funds.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA.

See Also: What is a stock portfolio tracker?

Get a free copy of the Zacks research report on Vivos Therapeutics (VVOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.